0001213900-26-062935.txt : 20260529 0001213900-26-062935.hdr.sgml : 20260529 20260529171041 ACCESSION NUMBER: 0001213900-26-062935 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20260527 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20260529 DATE AS OF CHANGE: 20260529 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Actinium Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001388320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 880378336 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36374 FILM NUMBER: 261045939 BUSINESS ADDRESS: STREET 1: 100 PARK AVE., 23RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: (646) 677-3870 MAIL ADDRESS: STREET 1: 100 PARK AVE., 23RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 FORMER COMPANY: FORMER CONFORMED NAME: Cactus Ventures, Inc. DATE OF NAME CHANGE: 20070130 8-K 1 ea0292691-8k_actinium.htm CURRENT REPORT
false 0001388320 0001388320 2026-05-27 2026-05-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 27, 2026

 

ACTINIUM PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-36374   74-2659386
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

100 Park Ave., 23rd Floor,

New York, New York 10017

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (646) 677-3870

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   ATNM   NYSE American LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

On May 27, 2026, Actinium Pharmaceuticals, Inc. (the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31, 2026, the Company reported stockholders’ equity of approximately $2.3 million, and had net losses in its last five fiscal years ended December 31, 2025.

 

In connection with its non-compliance with Sections 1003(a)(ii) and (iii) of the Company Guide, the Company must submit a plan by June 26, 2026, advising of actions it has taken or will take to regain compliance with the continued listing standards by November 27, 2027 (“Plan Period Deadline”). If NYSE Regulation determines to accept the plan, the Company will be notified in writing and will be subject to periodic reviews including quarterly monitoring for compliance with the plan.

 

If the Company does not submit a plan or if the plan is not accepted, delisting proceedings will commence. Furthermore, if the plan is accepted but the Company is not in compliance with the continued listing standards by the Plan Period Deadline, or if the Company does not make progress consistent with the plan during the plan period, NYSE American staff will initiate delisting proceedings as appropriate. The Company may appeal a staff delisting determination in accordance with Section 1010 and Part 12 of the Company Guide.

 

The Notice has no immediate effect on the listing or trading of the Company’s common stock, which will continue to trade on NYSE American under the symbol “ATNM,” subject to the Company’s compliance with the other continued listing requirements of NYSE American, and will continue to trade with a “.BC” indicator to denote that the Company is below compliance. The Company intends to submit a plan to NYSE American within the required timeframe.

 

There can be no assurance that the Company will be able to regain compliance with the applicable continued listing standards, that the Company will submit a plan that is accepted by NYSE American, that the Company will be able to comply with the terms of any accepted Plan, or that the Company will be able to maintain the listing of its common stock on NYSE American.

 

Item 7.01. Regulation FD Disclosure.

 

On May 29, 2026, pursuant to Sections 402(g) and 1009(j) of the Company Guide, the Company issued a press release announcing, among other things, its receipt of the Notice and providing an update on the development program for its ATNM-400 product candidate. The full text of the press release is set forth below.

 

The information furnished pursuant to this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Press Release dated May 29, 2026 (furnished pursuant to Item 7.01 of Form 8-K)
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

ACTINIUM PHARMACEUTICALS, INC.

 

Date: May 29, 2026

 

By: /s/ Sandesh Seth  
Name:  Sandesh Seth  
Title: Chairman and Chief Executive Officer  

 

2

 

 EX-99.1 2 ea029269101ex99-1.htm PRESS RELEASE DATED MAY 29, 2026

Exhibit 99.1

 

 

Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice

 

NEW YORK, May 29, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced it will provide a program update on its first-in-class Actinium-225 (225Ac) antibody radioconjugate, ATNM-400, highlighting new data that will be showcased across three presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting, taking place May 30-June 2, 2026, in Los Angeles, California. Two of the presentations showcase ATNM-400’s differentiated profile across prostate cancer and non-small cell lung cancer (NSCLC), while a third demonstrates the importance of radioconjugate optimization for radiotherapies in the context of the Company’s pipeline candidates.

 

With the SNMMI 2026 program now finalized, the Company is providing updated presentation details, including poster titles, presenters, dates, and times. The data to be presented reinforce the meaningful progress of the ATNM-400 program and its potential as a mutation-agnostic, pan-tumor therapy, while also demonstrating the strength of the underlying radioconjugate platform that supports Actinium’s broader pipeline. The Company anticipates multiple catalysts for ATNM-400, Actimab-A and Iomab-ACT in 2H:2026 that are expected to demonstrate the clinical potential of these programs.

 

ATNM-400 SNMMI 2026 Presentation Details

 

Poster Title: ATNM-400: A First-in-Class Non-PSMA Actinium-225 Antibody Radioconjugate Demonstrates Superior Efficacy to PSMA-617 Radioligands and ARPIs With Favorable Safety Profile in Prostate Cancer Models

Presenter: Sumit Mukherjee Ph.D., Actinium Pharmaceuticals, Inc.

Session: Oncology: Discovery & Translational Meet the Author Session

Date & Time: Tuesday, June 2, 2026 11:30am-12:15pm PT | Los Angeles, California

 

Poster Title: ATNM-400: A First-in-Class Actinium-225 Antibody Radioconjugate Demonstrating Durable, Mutation-Agnostic Anti-Tumor Activity in Non-Small Cell Lung Cancer Models

Presenter: Shiva Kazerounian Ph.D., Actinium Pharmaceuticals, Inc.

Session: Oncology: Discovery & Translational Meet the Author Session

Date & Time: Tuesday, June 2, 2026, 11:30am-12:15pm PT | Los Angeles, California

 

 

 

Poster Title: Optimizing Chelator-to-Antibody Ratio Improves Tumor Targeting and Pharmacokinetics of 225Ac-Labeled Antibodies

Presenter: Shiva Kazerounian Ph.D., Actinium Pharmaceuticals, Inc.

Session: MTA05 RPSC/CMIIT POPs and Science Pavilion Mixer

Date & Time: Sunday, May 31, 2026, 7:30-8:00pm PT | Los Angeles, California

 

The posters will be available on the Company website shortly after the presentations at https://ir.actiniumpharma.com/presentations-webinars.

 

NYSE American Continued Listing Standards Notice

 

Actinium also announced today that it has received a notice (the “Notice”) from the NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31, 2026, the Company reported stockholders’ equity of approximately $2.3 million and had net losses in its last five fiscal years ended December 31, 2025. The Notice also indicates that the Company is also not currently eligible for any exemption in Section 1003(a) of the Company Guide. The notice has no immediate effect on the listing or trading of the Company’s common stock on the NYSE American and the Company’s shares will continue to trade under the symbol “ATNM,” subject to compliance with other listing requirements of the Company Guide.

 

In connection with the non-compliance with Sections 1003(a)(ii) and (iii) of the Company Guide, the Company must submit a compliance plan by June 26, 2026, advising of actions the Company has taken or will take to regain compliance with the continued listing standards by November 27, 2027 (the “Plan Period Deadline”). If the NYSE American determines to accept the plan, the Company will be notified in writing and will be subject to periodic reviews, including quarterly monitoring, for compliance with the plan.

 

If the Company does not submit a plan or if the plan is not accepted, delisting proceedings will commence. Furthermore, if the plan is accepted but the Company is not in compliance with the continued listing standards by the Plan Period Deadline which is eighteen months from the receipt of the notice or November 27, 2027, or if the Company does not make progress consistent with the plan during the plan period, Exchange staff will initiate delisting proceedings as appropriate. The Company may appeal a staff delisting determination in accordance with Section 1010 and Part 12 of the Company Guide.

 

Actinium currently intends to submit a plan to regain compliance within the required timeframe. There can be no assurance that the Company will be able to achieve compliance with the NYSE American's continued listing standards within the required timeframe of eighteen months from date of receipt of the notice or November 27, 2027.

 

2

 

About Actinium Pharmaceuticals, Inc.

 

Actinium is a pioneer in targeted radiotherapies designed to improve outcomes for patients with cancer. The company employs a biology-driven approach to develop differentiated radiopharmaceuticals for solid tumors and hematologic malignancies. Its mission is to transform cancer treatment through innovative radioconjugates that maximize therapeutic efficacy while minimizing toxicity to healthy tissue by combining expertise in tumor biology, translational medicine, and radiochemistry. Since inception, Actinium has focused on developing innovative radiotherapies. Its pipeline reflects this strategy across three areas: (1) solid tumor therapeutics including ATNM-400 and Actimab-A with pan-tumor potential; (2) Actimab-A as a therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in collaboration with the National Cancer Institute (NCI); and (3) targeted conditioning agents including Iomab-B for bone marrow transplant and Iomab-ACT for cell and gene therapy conditioning. ATNM-400 targets a novel antigen distinct from PSMA and has demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Actimab-A has shown improved survival in relapsed/refractory AML with CLAG-M and is advancing toward a Phase 2/3 trial, with additional development ongoing through a CRADA with the NCI. Actinium is also advancing preclinical solid tumor programs and holds ~250 patents and patent applications, including intellectual property related to cyclotron-based production of Ac-225. For more information, please visit www.actiniumpharma.com.

 

Forward-Looking Statements

 

This press release may contain projections or other “forward-looking statements” within the meaning of the “safe-harbor” provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements, including statements as related to regaining compliance with the rules of the NYSE American and submission of a compliance plan, are based on management’s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium’s products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium’s filings with the Securities and Exchange Commission (the “SEC”), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

 

Investors: investorrelations@actiniumpharma.com

 

3

 

 GRAPHIC 3 ea029269101_ex99-1img1.jpg GRAPHIC begin 644 ea029269101_ex99-1img1.jpg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end EX-101.SCH 4 atnm-20260527.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 atnm-20260527_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 atnm-20260527_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.26.1
Cover
May 27, 2026
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 27, 2026
Entity File Number 001-36374
Entity Registrant Name ACTINIUM PHARMACEUTICALS, INC.
Entity Central Index Key 0001388320
Entity Tax Identification Number 74-2659386
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 100 Park Ave.,
Entity Address, Address Line Two 23rd Floor,
Entity Address, City or Town New York,
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10017
City Area Code 646
Local Phone Number 677-3870
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol ATNM
Security Exchange Name NYSEAMER
Entity Emerging Growth Company false
XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.26.1 html 1 23 1 false 0 0 false 0 false false R1.htm 00000001 - Document - Cover Sheet http://actiniumpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports atnm-20260527.xsd atnm-20260527_lab.xml atnm-20260527_pre.xml ea0292691-8k_actinium.htm http://xbrl.sec.gov/dei/2026 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0292691-8k_actinium.htm": { "nsprefix": "ATNM", "nsuri": "http://actiniumpharma.com/20260527", "dts": { "schema": { "local": [ "atnm-20260527.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd", "https://xbrl.fasb.org/srt/2026/elts/srt-roles-2026.xsd", "https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd", "https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd", "https://xbrl.fasb.org/us-gaap/2026/elts/us-roles-2026.xsd", "https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd", "https://xbrl.sec.gov/country/2026/country-2026.xsd", "https://xbrl.sec.gov/dei/2026/dei-2026.xsd", "https://xbrl.sec.gov/stpr/2026/stpr-2026.xsd" ] }, "labelLink": { "local": [ "atnm-20260527_lab.xml" ] }, "presentationLink": { "local": [ "atnm-20260527_pre.xml" ] }, "inline": { "local": [ "ea0292691-8k_actinium.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2026": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2026": 23 }, "report": { "R1": { "role": "http://actiniumpharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2026-05-27", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0292691-8k_actinium.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2026-05-27", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0292691-8k_actinium.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "AmendmentDescription", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "AmendmentFlag", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "AnnualInformationForm", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "CityAreaCode", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "CountryRegion", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentAccountingStandard", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentAnnualReport", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentPeriodEndDate", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentPeriodStartDate", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentQuarterlyReport", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentRegistrationStatement", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentShellCompanyReport", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentTransitionReport", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentType", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressAddressLine1", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressAddressLine2", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressAddressLine3", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressCityOrTown", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressCountry", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityCentralIndexKey", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityExTransitionPeriod", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityFileNumber", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityFilerCategory", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityPrimarySicNumber", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityRegistrantName", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityShellCompany", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntitySmallBusiness", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityVoluntaryFilers", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "Extension", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "LocalPhoneNumber", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "NoTradingSymbolFlag", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "PreCommencementTenderOffer", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "Security12bTitle", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "Security12gTitle", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "SecurityExchangeName", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "SecurityReportingObligation", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "SolicitingMaterial", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "TradingSymbol", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "WrittenCommunications", "presentation": [ "http://actiniumpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001213900-26-062935-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-26-062935-xbrl.zip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ea0292691-8k_actinium_htm.xml IDEA: XBRL DOCUMENT 0001388320 2026-05-27 2026-05-27 false 0001388320 8-K 2026-05-27 ACTINIUM PHARMACEUTICALS, INC. DE 001-36374 74-2659386 100 Park Ave., 23rd Floor, New York, NY 10017 646 677-3870 false false false false Common Stock, par value $0.001 per share ATNM NYSEAMER false